Misoprostol for prevention and treatment of postpartum hemorrhage: What do we know? What is next?

被引：13
作者：
Raghavan, Sheila [1 ]
Abbas, Dina [1 ]
Winikoff, Beverly [1 ]
机构：
[1] Gynu Hlth Projects, New York, NY 10010 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS | 2012年 / 119卷
关键词：
Misoprostol; Postpartum hemorrhage; Prevention; Treatment; ORAL MISOPROSTOL; 3RD STAGE; LABOR;
D O I：
10.1016/j.ijgo.2012.03.013
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Misoprostol is an effective and safe uterotonic for the prevention and treatment of postpartum hemorrhage (PPH). A 600-mu g oral dose of misoprostol has been shown to prevent PPH in community-based randomized controlled trials. An 800-mu g sublingual dose of misoprostol appears to be a good first-line treatment for controlling PPH. Adverse effects after use of misoprostol for PPH prevention or treatment may include shivering and fever. These effects are transient, resolve on their own, and are not life threatening. Misoprostol can play an important role in settings with limited access to oxytocin, and where there is no other option for PPH care. (c) 2012 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：S35 / S38
页数：4
相关论文
共 23 条
  • [1] Prevention of postpartum hemorrhage with misoprostol
    Alfirevic, Z.
    Blum, J.
    Walraven, G.
    Weeks, A.
    Winikoff, B.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2007, 99 : S198 - S201
  • [2] Prevention and treatment of post-partum haemorrhage - New advances for low resource settings
    不详
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2007, 97 (02) : 160 - 163
  • [3] [Anonymous], 2009, PREV MAN POSTP HAEM
  • [4] [Anonymous], 2006, Obstet Gynecol, V108, P1039, DOI DOI 10.1097/00006250-200610000-00046
  • [5] Treatment of postpartum hemorrhage with misoprostol
    Blum, J.
    Alfirevic, Z.
    Walraven, G.
    Weeks, A.
    Winikoff, B.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2007, 99 : S202 - S205
  • [6] Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial
    Blum, Jennifer
    Winikoff, Beverly
    Raghavan, Sheila
    Dabash, Rasha
    Ramadan, Mohamed Cherine
    Dilbaz, Berna
    Dao, Blami
    Durocher, Jill
    Yalvac, Serdar
    Diop, Ayisha
    Dzuba, Ilana G.
    Ngoc, Nguyen Thi Nhu
    [J]. LANCET, 2010, 375 (9710) : 217 - 223
  • [7] Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial
    Derman, Richard J.
    Kodkany, Bhalchandra S.
    Goudar, Shivaprasad S.
    Geller, Stacie E.
    Naik, Vijaya A.
    Bellad, M. B.
    Patted, Shobhana S.
    Patel, Ashlesha
    Edlavitch, Stanley A.
    Hartwell, Tyler
    Chakraborty, Hrishikesh
    Moss, Nancy
    [J]. LANCET, 2006, 368 (9543) : 1248 - 1253
  • [8] High fever following postpartum administration of sublingual misoprostol
    Durocher, J.
    Bynum, J.
    Leon, W.
    Barrera, G.
    Winikoff, B.
    [J]. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2010, 117 (07) : 845 - 852
  • [9] Prostaglandins for preventing postpartum haemorrhage
    Guelmezoglu, A. M.
    Forna, F.
    Villar, J.
    Hofmeyr, G. J.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03):
  • [10] Hofmeyr GJ, 2009, B WORLD HEALTH ORGAN, V87, P666, DOI [10.2471/BLT.08.055715, 10.2471/BLT.08.062562]
123